Single Arm, Multicenter Phase II Study Investigating the Efficacy and Safety of a Novel Therapeutic Scheme in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization in Combination With CisGem and Durvalumab (MEDI4736)
Latest Information Update: 28 May 2024
At a glance
- Drugs Cisplatin (Primary) ; Durvalumab (Primary) ; Gemcitabine (Primary)
- Indications Cholangiocarcinoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms PM-CARE
Most Recent Events
- 28 May 2024 Last checked against :ClinicalTrials.gov: US National Institutes of Health
- 23 May 2024 Status changed from not yet recruiting to recruiting.
- 23 Apr 2024 New trial record